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received no medical intervention (WW-no treatment) and 
the impact of baseline variables on IPSS determined.
Results The adjusted mean decrease in IPSS, BII and IPSS-
Q8 at each post-baseline visit over 24 months appeared 
greater in the FDC (n = 369) and WW-no treatment groups 
(n = 144) than in the WW-TAM group (n = 229). IPSS 
improvements appeared similar in the FDC group and 
WW-no treatment subgroup, except in patients with the 
greatest degree of bother at baseline (BII 7–13).
Conclusion BII at baseline may be a more relevant indi-
cator than symptom severity as to whether a patient with 
moderate symptoms should receive medical therapy or not.
Keywords Benign prostatic hyperplasia · BPH Impact 
Index · Dutasteride · Lower urinary tract symptoms · 
Tamsulosin · Watchful waiting
Abbreviations
BII  BPH Impact Index
BPE  Benign prostatic enlargement
BPH  Benign prostatic hyperplasia
FDC  Fixed-dose combination
IPSS  International Prostate Symptom Score
LUTS  Lower urinary tract symptoms
PSA  Prostate-specific antigen
QoL  Quality of life
WW  Watchful waiting
Introduction
More than 50 % of men aged ≥60 years have histological 
evidence of benign prostatic hyperplasia (BPH). BPH can 
be associated with benign prostatic enlargement (BPE), 
which can result in lower urinary tract symptoms (LUTS) 
Abstract 
Purpose To investigate (in a post hoc analysis of the 2-year 
CONDUCT study) the characteristics and clinical out-
comes of men with moderately symptomatic benign pros-
tatic hyperplasia (BPH) at risk of progression who benefit-
ted from lifestyle changes alone.
Methods Patients were given lifestyle advice and rand-
omized to a fixed-dose combination (FDC) of dutasteride 
and tamsulosin or watchful waiting (WW) and followed 
for 24 months. Patients in the WW group were escalated to 
tamsulosin if any follow-up International Prostate Symptom 
Score (IPSS) was equal or greater than the baseline value. 
Improvements in symptoms (change in IPSS) and quality of 
life [measured by BPH Impact Index (BII) and question 8 
of the IPSS (IPSS-Q8)] were analysed in the FDC group, 
men who initiated tamsulosin (WW-TAM) and men who 
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such as weak stream and hesitancy; some men may also 
experience LUTS associated with storage, such as increased 
urgency, frequency and nocturia. These symptoms can sig-
nificantly diminish a person’s quality of life (QoL) [1, 2].
The optimal time point to initiate medical therapy of 
BPH is a matter of debate [3]. Although guidelines recom-
mend a conservative approach for men with minimal symp-
toms [4, 5], several observations argue that early interven-
tion may be an appropriate option for some patients [6, 7].
The CONDUCT study was performed to investigate 
whether there was a difference in symptomatic improve-
ment from baseline, as measured by the International Pros-
tate Symptom Score (IPSS), among treatment-naïve men 
with moderately symptomatic BPH at risk of progression, 
who were given lifestyle advice and either immediate treat-
ment with a fixed-dose combination (FDC) of dutasteride 
and tamsulosin or managed with watchful waiting (WW) 
with protocol-defined initiation of tamsulosin monotherapy 
if symptoms did not improve. The results of this study have 
previously been reported [8]. Notably, over one-third of 
men managed with WW in CONDUCT had symptomatic 
improvement without any pharmacological intervention, 
i.e. with lifestyle advice alone [8].
The mechanisms leading to an improvement in symp-
toms without pharmacologic intervention are poorly under-
stood; however, condition-, patient- and lifestyle-specific 
factors could be involved [3]. To investigate this further, 
we report a post hoc analysis of CONDUCT 2-year data 
revealing the demographics, disposition and clinical out-
comes of men who received immediate intervention with 
FDC, initiated tamsulosin monotherapy or received no 




The design of the CONDUCT study (GlaxoSmithKline 
FDC114615; NCT01294592) has been reported [8]. Eli-
gible men [aged ≥50 years, confirmed clinical diagnosis 
of BPH, moderate LUTS (IPSS of 8–19), prostate volume 
≥30 mL and total serum prostate-specific antigen (PSA) 
level of ≥1.5 ng/mL] were randomized 1:1 to self-admin-
ister a FDC of dutasteride 0.5 mg and tamsulosin 0.4 mg 
QD (Duodart®, GlaxoSmithKline), or WW with initiation 
of tamsulosin 0.4 mg QD if any IPSS after randomization 
was the same or greater than the baseline value. Lifestyle 
advice was provided at baseline to all patients.
Patients visited the clinic 4 weeks after randomization 
and at 13-week intervals thereafter, for up to 24 months. 
Patient-reported symptoms, symptom impact and 
BPH-related QoL were assessed at every visit using the 
last observation carried forward method. Data on adverse 
events were collected from first administration of study 
treatment (FDC or tamsulosin) until discontinuation and 
have been presented previously [8]. Safety data were not 
scheduled to be collected for patients in the WW group 
who received no drug.
Post hoc data analyses
Symptomatic improvement, as measured by IPSS, was 
investigated in the FDC group, the WW subgroup who ini-
tiated tamsulosin (WW-TAM) and the WW subgroup who 
did not receive medical intervention (WW-no treatment). 
As the CONDUCT study was not powered to assess treat-
ment effects in or across the WW-TAM and WW-no treat-
ment subgroups, no formal statistical analyses were per-
formed. Data from patients in the WW-TAM and WW-no 
treatment subgroups were supplemental and are provided 
for descriptive purposes only.
Data were summarised overall and by baseline sub-
groups as tabular displays and figures in terms of mean 
change from baseline in IPSS, BPH Impact Index (BII) 
and question 8 of the IPSS (IPSS-Q8). Changes in IPSS 
were also summarised according to the categorical sub-
groups of age (<65, ≥65 years) and BII (0–3, 4–6 or 7–13 
at baseline).
Results
Patient demographics and disposition
In all, 742 patients were randomized into CONDUCT (369 
and 373 in the FDC and WW groups, respectively). Of the 
373 patients randomized to WW, 229 (61.4 %) initiated 
tamsulosin, mostly within the first 6 months of the study. 
Of 190 patients who started tamsulosin within 6 months of 
randomization, 125 (66 %) started in month 1, 45 (24 %) in 
month 3 and 20 (11 %) in month 6. Baseline characteristics 
were generally similar between the three groups (Table 1). 
Although the mean IPSS at baseline was the same for men 
in the WW-TAM and WW-no treatment subgroups, men in 
the WW-no treatment subgroup tended to be younger and 
less bothered by their symptoms at baseline.
Changes in IPSS, BII and IPSS‑Q8
The adjusted mean decrease (improvement) in IPSS at 
each post-baseline visit over 24 months appeared greater 
in the WW-no treatment subgroup than in the WW-TAM 
subgroup and very similar between the FDC group and 
WW-no treatment subgroup (Fig. 1a). At month 24, the 
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mean change in IPSS was −5.6 for patients in the FDC 
group, −5.1 for patients in the WW-no treatment subgroup 
and −2.7 among patients who received tamsulosin.
The improvement in BII and IPSS-Q8 at each post-
baseline visit over 24 months appeared greater in the FDC 
group than in either the WW-no treatment or the WW-TAM 
subgroups and greater in the WW-no treatment subgroup 
than in the WW-TAM subgroup (Fig. 1b, c).
Impact of baseline variables on changes in IPSS
The baseline characteristics of men aged ≥65 or <65 years 
of age were generally comparable (Table 2). Although 
men aged <65 years were more bothered by their urinary 
problems at baseline than older men (BII score of 5.1 vs 
4.3), this did not translate into a difference in baseline 
IPSS. In the FDC and WW-no treatment subgroups, the 
mean IPSS was lower at each post-baseline visit in patients 
aged <65 years than in patients aged ≥65 years. Between 
baseline and month 24, the IPSS for patients aged <65 
and ≥65 years improved by 6.6 and 4.8 points for patients 
in the FDC group, 5.5 and 4.8 points for patients in the 
WW-no treatment subgroup and 2.9 and 2.6 points in the 
WW-TAM subgroup (Fig. 2a; Table 3).
Table 3 shows the mean IPSS change from baseline at 
24 months according to various categories of baseline char-
acteristics. Symptom improvement in the WW-no treatment 
subgroup was similar across the different categories, with 
no obvious signals of a baseline characteristic that indicated 
better symptom outcomes. IPSS improvements generally 
appeared greater in the FDC group and WW-no treatment 
subgroup than in the WW-TAM subgroup and were similar 
in the FDC group and WW-no treatment subgroups, except 
in patients with the greatest degree of bother at baseline. 
Between baseline and month 24, the IPSS for patients with 
baseline BII of 0–3, 4–6 and 7–13 improved by 4.3, 5.4 and 
7.1 points for patients in the FDC group, 5.0, 5.3 and 5.1 
points for patients in the WW-no treatment subgroup and 
1.6, 2.7 and 4.1 points in the WW-TAM subgroup (Fig. 2b).
Table 1  Baseline characteristics
Variable FDC (n = 369) WW-TAM  
(n = 229)
WW-no treatment  
(n = 144)
All (N = 742)
Age (years) 66.3 66.7 65.3 66.2
PSA (ng/mL) 3.9 3.8 3.6 3.8
Prostate volume (mL) 51.0 52.6 52.6 51.8
Mean IPSS 13.2 12.9 12.9 13.1
Mean BII score 4.8 4.7 4.0 4.6
 BII 0–3 [n (%)] 123 (33) 75 (33) 68 (47) 266 (36)
 BII 4–6 [n (%)] 132 (36) 94 (41) 37 (26) 263 (35)
 BII 7–13 [n (%)] 114 (31) 60 (26) 39 (27) 213 (29)
IPSS-Q8 3.2 3.1 2.9 3.1
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Fig. 1  Mean change from baseline in a IPSS, b BII and c IPSS-Q8
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Table 2  Baseline characteristics of patients according to age
≥65 years <65 years
FDC WW-no  
treatment
WW-TAM All FDC WW-no  
treatment
WW-TAM All
Patients (n) 210 79 140 429 159 65 89 313
Age (years) 71.8 70.6 71.5 71.5 59.0 58.9 59.3 59.1
Weight (kg) 79.78 81.63 82.5 81.01 83.37 84.02 85.26 84.05
Body mass index 26.93 27.87 27.87 27.39 27.73 28.07 28.13 27.91
Time since first LUTS (years) 4.2 4.0 4.5 4.3 3.4 3.0 2.7 3.1
Time since BPH diagnosis (years) 3.0 2.6 3.0 2.9 2.3 2.3 2.0 2.2
PSA (ng/mL) 3.9 3.7 4.0 3.9 3.8 3.5 3.5 3.6
IPSS 13.0 12.8 13.0 13.0 13.4 13.0 12.8 13.1
Prostate volume (mL) 51.6 56.9 55.2 53.7 50.3 47.5 48.6 49.3
BII 4.6 3.4 4.2 4.3 5.0 4.7 5.3 5.1
IPSS-Q8 3.1 2.7 3.0 3.0 3.2 3.1 3.2 3.2
Fig. 2  Mean change from 
baseline in IPSS according to 
a age (solid line ≥65 years; 
broken line <65 years) and b 
BII at baseline
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Discussion
Symptomatic improvements among men in the WW-no 
treatment subgroup appeared similar to those in men who 
received FDC therapy and better than those in the WW-
TAM subgroup. There are a number of possible explana-
tions for this. As previously reported [8], men who initiated 
tamsulosin tended to be older and have more bothersome 
symptoms at baseline. It is possible that younger men 
are better able to tolerate their symptoms; as a result, the 
degree of bother does not translate into changes in IPSS 
and treatment with tamsulosin is not indicated. By contrast, 
the threshold between the degree of bother and impact 
on IPSS may be lower in elderly men; i.e. although they 
may not have required medical intervention, the impact of 
symptoms on their general well-being may have led them 
to actively seek treatment. Another possible explanation 
relates to the study design. The WW-no treatment subgroup 
is composed of men who, from one study visit to the next, 
exhibited a lower score compared with baseline. CON-
DUCT selected a group of men in this arm who, perhaps 
by random choice, had a baseline symptom score higher 
than their true symptom status before enrolment. Over 
the course of the study, they never reached the high score 
recorded at baseline. Since all men whose symptom score 
stayed the same or increased were eliminated from this 
subgroup; this may have resulted in a remarkable (albeit 
artificial) ‘improvement’ that cannot be attributed to a pla-
cebo effect.
In the present post hoc analysis, symptom improvement 
was analysed according to age and BII at baseline. The 
data show that in terms of active treatment, FDC therapy 
appeared more effective than tamsulosin monotherapy in 
improving symptoms and lessening the degree of associ-
ated bother across all baseline subgroups. FDC therapy also 
offered an advantage over no treatment in younger patients, 
which seemed more apparent in men who were largely 
bothered by their symptoms at baseline (BII 7–13) or were 
less willing to spend the rest of their lives with the symp-
toms they had at baseline (IPSS-Q8 ≥ 4).
Patients with a higher BII at baseline also have a higher 
IPSS since the two measures are correlated. Among men 
who received immediate intervention with FDC, the abso-
lute change in IPSS increased with increasing BII at base-
line. This effect, however, was not observed among men 
in the WW-no treatment subgroup. The larger relative 
improvement in IPSS for men who received FDC treat-
ment and had a BII score of 7–13 at baseline is a novel and 
unique insight provided by this post hoc analysis. Although 
further data are needed, these findings suggest that rather 
than symptom severity at baseline, the degree of associated 
bother (as determined by BII) may be a more relevant indi-
cator as to whether a patient will benefit from treatment or 
not.
After initial symptoms develop, many patients will 
postpone a visit to the physician and try to adjust their 
lifestyle to self-manage their symptoms, only seeking 
medical advice, when their LUTS eventually become too 
bothersome [9]. Ensuring men are aware of the importance 
of lifestyle advice in managing their symptoms is therefore 
an important focus, and communication plays an essential 
role. For example, doctors who are able to spend more time 
Table 3  Mean IPSS change from baseline at 24 months according to baseline characteristics
Baseline characteristic Mean change in IPSS from baseline at month 24 (patients, n)
Patients aged ≥65 years at baseline Patients aged <65 years at baseline
FDC WW-All WW-no  
treatment
WW-TAM FDC WW-All WW-no  
treatment
WW-TAM
≥ or <65 years −4.8 (203) −3.3 (216) −4.8 (76) −2.6 (140) −6.6 (156) −4.0 (152) −5.5 (63) −2.9 (89)
IPSS <13 −3.3 (92) −1.7 (108) −3.9 (42) −0.4 (66) −4.7 (77) −3.4 (69) −5.1 (31) −2.0 (38)
IPSS ≥13 −5.9 (111) −4.9 (108) −5.9 (34) −4.5 (74) −8.5 (79) −4.5 (83) −5.9 (32) −3.7 (51)
BII 0–3 −4.1 (69) −2.7 (98) −4.4 (43) −1.4 (55) −4.6 (49) −4.2 (43) −6.1 (23) −2.0 (20)
BII 4–6 −4.5 (78) −3.7 (77) −5.9 (20) −3.0 (57) −6.9 (52) −2.9 (53) −4.5 (16) −2.2 (37)
BII 7–13 −5.9 (56) −4.0 (41) −4.3 (13) −3.9 (28) −8.3 (55) −4.9 (56) −5.6 (24) −4.3 (32)
IPSS Q8 <4 −4.4 (133) −3.0 (146) −4.7 (54) −1.9 (92) −5.4 (96) −4.0 (96) −5.4 (40) −2.9 (56)
IPSS Q8 ≥4 −5.4 (70) −4.1 (70) −4.9 (22) −3.7 (48) −8.7 (60) −4.1 (56) −5.7 (23) −3.0 (33)
Prostate volume <40 mL −4.7 (67) −3.6 (49) −4.7 (17) −3.0 (32) −5.9 (54) −4.2 (47) −5.3 (21) −3.3 (26)
Prostate volume ≥40 mL −4.8 (135) −3.3 (167) −4.8 (59) −2.4 (108) −7.0 (102) −3.9 (105) −5.6 (42) −2.8 (63)
PSA <3 ng/mL −3.8 (78) −4.2 (82) −5.1 (31) −3.6 (51) −6.2 (69) −4.3 (77) −6.0 (31) −3.1 (46)
PSA ≥3 ng/mL −5.3 (125) −2.8 (134) −4.6 (45) −1.9 (89) −7.0 (87) −3.7 (75) −5.0 (32) −2.8 (43)
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with their patients may be more successful in motivating 
them to adopt lifestyle changes. The extent to which the 
advice was incorporated or adhered to in the CONDUCT is 
unknown. Further analyses to determine whether the social, 
educational or professional status of a patient affected the 
adoption of lifestyle changes would be useful.
There are several limitations that should be considered 
when interpreting these results. Study-related limitations 
include the open-label design and the lack of a placebo 
arm. Limitations of these analyses include their post hoc 
nature and the absence of formal statistical testing. As the 
analyses described herein were not powered to detect dif-
ferences, data were provided for descriptive purposes only 
and must be interpreted accordingly. Of note, statistical 
analyses of subgroups often result in the misinterpretation 
or misuse of clinical data. Since the original randomisation 
no longer applies, newly defined subgroups are likely to be 
biased; furthermore, when multiple subgroup analyses are 
performed, the probability of a false positive finding can be 
substantial [10].
 In conclusion, some patients with moderately symp-
tomatic BPH at risk of progression benefit from lifestyle 
advice alone. In this analysis, they are characterised by 
having a lower BII score at baseline; a novel finding that 
provides useful information for the care of patients and 
for future research. The CombAT study in men with mod-
erate-to-severe symptoms showed symptomatic improve-
ment with combination therapy, irrespective of BII [11]. 
Here, men with moderate symptoms but a higher bother 
score (7–13) appeared to have a substantial improvement 
in symptoms with combination therapy, even with lifestyle 
changes. The results of CONDUCT support guidelines that 
recommend conservative management for men with mild 
symptoms and those who are not bothered by moderate 
symptoms [4, 5] and suggest that using BII to further refine 
the selection of patients with moderate symptoms may pro-
vide a pathway to preventing the suboptimal management 
of BPH.
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